Thymosin α1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3–MMP2 signaling

OncoTargets and Therapy

Volumn 11, Issue , 2018, Pages 7255-7270

  Bo, Cong ^a   Wu, Qiang ^a   Zhao, Hai ^a   Li, Xuebing ^b   Zhou, Qinghua ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 2; Non small cell lung cancer; Programmed cell death ligand 1; STAT3; Thymosin 1

Indexed keywords

GELATINASE A; SMALL INTERFERING RNA; STAT3 PROTEIN; THYMOSIN ALPHA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALB/C NUDE MOUSE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE KNOCKDOWN; HUMAN; HUMAN CELL; IN VIVO STUDY; L9981 CELL LINE; LUNG NON-SMALL CELL CARCINOMA CELL LINE; METASTASIS INHIBITION; MOUSE; NCI-H1299 CELL LINE; NL9980 CELL LINE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPC-A1 CELL LINE; TRANSWELL ASSAY; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING ASSAY;

EID: 85057751873     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S177943     Document Type: Article

References (42)

1. GLOBOCAN [webpage on the Internet]. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed September 28, 2018.
2. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27–iii39.
3. Bai X, Meng L, Sun H, Li Z, Zhang X, Hua S. MicroRNA-196b inhibits cell growth and metastasis of lung cancer cells by targeting Runx2. Cell Physiol Biochem. 2017;43(2):757–767.
4. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–644.
5. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
6. Pierluigi B, D’Angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010;1194:1–5.
7. Goldstein AL, Slater FD, White A, Preparation WA. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci U S A. 1966;56(3):1010–1017.
8. Hooper JA, Mcdaniel MC, Thurman GB, Cohen GH, Schulof RS, Goldstein AL. Purification and properties of bovine thymosin. Ann N Y Acad Sci. 1975;249:125–144.
9. Fan YZ, Chang H, Yu Y, Liu J, Wang R. Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides. 2006;27(9):2165–2173.
10. Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides. 2010;31(11): 2151–2158.
11. Moretti S, Oikonomou V, Garaci E, Romani L. Thymosin α1: burying secrets in the thymus. Expert Opin Biol Ther. 2015;15(Suppl 1):51–58.
12. Jiang J, Wang X, Tian J, Li L, Lin Q. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Thorac Cancer. 2011;2(4):213–220.
13. Cheepsattayakorn A, Cheepsattayakorn R. Lung cancer chemotherapy, new treatment and related patents. Recent Pat Anticancer Drug Discov. 2014;9(3):372–381.
14. Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. 1993;53(21):5214–5218.
15. Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis. 2015;20(8):1109–1121.
16. Moody TW. Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann N Y Acad Sci. 2007;1112:297–304.
17. Zhou Q, Wang Y, Che G, et al. Establishment and their biological characteristics of clonal cell subpopulations (NL9980 and L9981) from a human lung large cell carcinoma cell line (WCQH-9801). Zhongguo Fei Ai Za Zhi. 2003;6(6):464–468.
18. D L, X X. Effect of thymosin a1 on the apoptosis of lung cancer cell A549. Chin J Clin Pharmacol. 2016;32(19):1776–1779.
19. Abdelhamed S, Ogura K, Yokoyama S, Saiki I, Hayakawa Y. AKT-STAT3 pathway as a downstream target of EGFR signaling to regulate PD-L1 expression on NSCLC cells. J Cancer. 2016;7(12): 1579–1586.
20. Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21(17): 4014–4021.
21. Garaci E, Pica F, Matteucci C. Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):31–39.
22. Lin K, Cheng J, Yang T, Li Y, Zhu B. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015;463(1–2):95–101.
23. Soria JC, Marabelle A, Brahmer JR, Gettinger S. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res. 2015;21(10): 2256–2262.
24. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28(3):682–688.
25. Okuma Y, Hishima T, Kashima J, Homma S. High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. Cancer Immunol Immunother. 2018;67(3):495–505.
26. Takamori S, Toyokawa G, Okamoto I, et al. Clinical significance of PD-L1 expression in brain metastases from non-small cell lung cancer. Anticancer Res. 2018;38(1):553–557.
27. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.
28. Asgarova A, Asgarov K, Godet Y, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018;7(5):e1423170.
29. Kim S, Koh J, Kim MY, et al. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol. 2016;58:7–14.
30. Zhang J, Gao J, Li Y, et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015;6(4):534–538.
31. Zhao L, Li C, Liu F, et al. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther. 2017;10:2115–2126.
32. Lee MM, Chen YY, Liu PY, Hsu S, Sheu MJ. Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2. Chem Biol Interact. 2015;236:19–30.
33. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17): 1260–1270.
34. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(Suppl):S42–S51.
35. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/ MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 1995;64(5):355–359.
36. Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010;3(8):775–781.
37. Poudel B, Ki HH, Luyen BT, Lee YM, Kim YH, Kim DK. Triticumoside induces apoptosis via caspase-dependent mitochondrial pathway and inhibits migration through downregulation of MMP2/9 in human lung cancer cells. Acta Biochim Biophys Sin. 2016;48(2):153–160.
38. Jung O, Lee J, Lee YJ, et al. Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenua-tions of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways. Bioorg Med Chem Lett. 2016;26(16): 3963–3967.
39. Lee KR, Lee JS, Song JE, Ha SJ, Hong EK. Inonotus obliquus-derived polysaccharide inhibits the migration and invasion of human non-small cell lung carcinoma cells via suppression of MMP-2 and MMP-9. Int J Oncol. 2014;45(6):2533–2540.
40. Byun HJ, Darvin P, Kang DY, et al. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol Rep. 2017;37(6): 3270–3278.
41. Yan W, Tu B, Liu YY, et al. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone Res. 2013;1(4):362–370.
42. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504–535.